SCHEDULE 13G/A: Dr. David D. Chang and Affiliated Trusts Report 5.0% Beneficial Ownership in Allogene Therapeutics
Beneficial Ownership Report
Dr. David D. Chang, along with the Chang 2006 Family Trust, JEC 2019 Trust, and RTC 2019 Trust, has filed an amended Schedule 13G, reporting a combined beneficial ownership of 5.0% of Allogene Therapeutics, Inc.'s common stock as of March 31, 2025.
Summary
- This document is an Amendment No. 3 to a Schedule 13G filing for Allogene Therapeutics, Inc. common stock (CUSIP 019770106).
- The reporting persons are David D. Chang, M.D., Ph.D., Chang 2006 Family Trust, JEC 2019 Trust, and RTC 2019 Trust, acting as a group.
- As of March 31, 2025, Dr. David D. Chang beneficially owns an aggregate of 11,043,100 shares of Allogene Therapeutics, Inc. common stock.
- This aggregate amount represents 5.0% of the company's common stock outstanding.
- Dr. Chang's beneficial ownership includes 5,319,786 shares issuable within 60 days from the exercise of stock options.
- It also includes shares beneficially owned by the three trusts where Dr. Chang serves as co-trustee: Chang 2006 Family Trust (1,201,108 shares, 0.5%), JEC 2019 Trust (856,044 shares, 0.4%), and RTC 2019 Trust (856,044 shares, 0.4%).
- The percentage of class is calculated based on 217,264,738 shares of common stock outstanding as of March 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-K filed on March 13, 2025.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership, indicating a significant, passive stake by a key individual and affiliated trusts. It does not contain information that would significantly alter the company's operational or financial sentiment, but the maintenance of a substantial insider stake can be viewed as a neutral to slightly positive signal of confidence.
Positives
- Dr. David D. Chang, a key individual, maintains a significant beneficial ownership of 5.0% in Allogene Therapeutics, indicating continued alignment with shareholder interests.
- The inclusion of 5,319,786 shares from exercisable stock options within 60 days suggests a potential increase in Dr. Chang's direct stake.
Negatives
- No specific negative financial or operational information is disclosed in this beneficial ownership filing.
Risks
- This filing does not contain information regarding operational or financial risks of Allogene Therapeutics, Inc.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.
Management Comments
- No specific management comments or notable quotes are provided in this beneficial ownership filing beyond the certification statement.
Industry Context
This Schedule 13G filing primarily concerns the beneficial ownership stake of Dr. David D. Chang and affiliated trusts in Allogene Therapeutics, Inc. It does not provide broader industry context or trends, but rather details a significant individual and group holding within the biotechnology sector.
Comparison to Industry Standards
- This beneficial ownership filing does not provide information suitable for comparison to industry-specific financial or operational benchmarks.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- No litigation or regulatory matters are disclosed in this beneficial ownership filing.
Related Party Transactions
- The filing details beneficial ownership by trusts affiliated with Dr. David D. Chang, who is also a reporting person. This constitutes a disclosure of related party holdings rather than specific transactions.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on significant beneficial ownership stakes held by Dr. David D. Chang and affiliated trusts.
Next Steps
- This filing is a regulatory disclosure of beneficial ownership and does not outline specific future actions, events, or milestones for Allogene Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-03-07 | Date as of which 217,264,738 shares of common stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-K. |
| 2025-03-13 | Date the Issuer's Quarterly Report on Form 10-K was filed, reporting shares outstanding. |
| 2025-03-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-05-09 | Date the Schedule 13G/A Amendment No. 3 was signed and filed. |
Keywords
Allogene Therapeutics, Common Stock, Schedule 13G, Beneficial Ownership, David D. Chang, Institutional Ownership, SEC Filing, ALLG, Biotechnology, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.